Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05106101 · ClinicalTrials.gov registry record · Phase 1

L-glutamine Treatment in Patients With Diverticulosis

A Phase 1 study of Diverticulosis, Colonic, sponsored by Emmaus Medical.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
3
Study locations

NCT05106101: Completed Phase 1 study of Diverticulosis, Colonic, sponsored by Emmaus Medical.

NCT05106101 is a Phase 1 study of Diverticulosis, Colonic that has completed, run by Emmaus Medical. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05106101, a Phase 1 study of Diverticulosis, Colonic, has completed, sponsored by Emmaus Medical.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
3
Study locations

Study Summary

The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment for patients with diverticulosis.

Primary Outcome

Number of diverticula for both the descending colon and sigmoid will be counted at baseline, at 6 months and at 12 months

Conditions Studied

Interventions

  • DRUG L-glutamine

Study Locations (3)

California

  • The Lundquist Institute at Harbor-UCLA Medical Center - Torrance
  • Ventura Clinical Trials - Ventura

Texas

  • Clinical Trials of Texas, Inc. - San Antonio

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2019-07-19
Est. Completion 2022-12-30
Phase Phase 1
Emmaus Medical

4 total trials

What the finished NCT05106101 record still lists

NCT05106101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Diverticulosis, Colonic appearing as the primary indexed condition, and to 1 intervention - of which L-glutamine is the first listed.

NCT05106101 reports a single indexed study location in California, Texas.

Frequently Asked Questions

What is clinical trial NCT05106101 about?

NCT05106101 is a clinical study titled "L-glutamine Treatment in Patients With Diverticulosis". The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment for patients with diverticulosis.

What is the current status of trial NCT05106101?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-07-19. Estimated completion is 2022-12-30.

What conditions does trial NCT05106101 study?

This clinical trial studies the following conditions: Diverticulosis, Colonic.

What interventions are being tested in trial NCT05106101?

The interventions under investigation include: L-glutamine (DRUG).

Who is sponsoring clinical trial NCT05106101?

This trial is sponsored by Emmaus Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05106101 being conducted?

This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT05106101's enrollment target sits among peer trials

9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05106101, the US trial registry maintained by the National Library of Medicine. NCT05106101 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.